Advanced Biomed Inc. Common Stock (ADVB)
Automate Your Wheel Strategy on ADVB
With Tiblio's Option Bot, you can configure your own wheel strategy including ADVB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADVB
- Rev/Share 0.0
- Book/Share 0.1388
- PB 2.1322
- Debt/Equity 0.0186
- CurrentRatio 1.9193
- ROIC -0.0296
- MktCap 6405440.0
- FreeCF/Share -0.1998
- PFCF -1.4818
- PE -60.5343
- Debt/Assets 0.0089
- DivYield 0
- ROE -0.0377
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Published: December 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “Hong Kong Subsidiary”), for an aggregate purchase price …
Read More
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the closing of its initial public offering (the "Offering") of 1,640,000 shares of common stock (the “Shares”), at a public offering price of $4.00 per share for total gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. The Shares began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol “ADVB.”
Read More
About Advanced Biomed Inc. Common Stock (ADVB)
- IPO Date 2025-03-06
- Website https://www.advanbiomed.com
- Industry Medical - Diagnostics & Research
- CEO Yi Lu
- Employees 40